The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.
PO Box 1069
11 East State Street
Sherburne, NY 13460
The Neuroleptic Malignant Syndrome Information Service was founded in 1997 by the Malignant Hyperthermia Association of the United States (MHAUS) to advance awareness of neuroleptic malignant syndrome. This is a life-threatening neurological disorder often caused by an adverse reaction to neuroleptic or antipsychotic drugs. The goals of NMSIS include to develop and manage an NMS hotline, to encourage and support research to determine the cause of NMS, to develop a standard protocol for NMS, and increase awareness of this rare disorder.
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.